Relationship between CCM3 expression and angiogenesis in esophageal squamous cell carcinoma and its possible mechanism.

IF 3 3区 医学 Q3 ONCOLOGY International Journal of Clinical Oncology Pub Date : 2026-10-01 Epub Date: 2026-07-08 DOI:10.1007/s10147-026-03132-w
Muhammad Saud Tabish, Yiwei Li, Na Zhao, Yichen Hong, Jiao Shu, Chenbo Yang, Zexin Sun, Xiaonan Liu, Miaomiao Sun, Kuisheng Chen
{"title":"Relationship between CCM3 expression and angiogenesis in esophageal squamous cell carcinoma and its possible mechanism.","authors":"Muhammad Saud Tabish, Yiwei Li, Na Zhao, Yichen Hong, Jiao Shu, Chenbo Yang, Zexin Sun, Xiaonan Liu, Miaomiao Sun, Kuisheng Chen","doi":"10.1007/s10147-026-03132-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Angiogenesis is essential for esophageal squamous cell carcinoma (ESCC) progression, yet clinically actionable regulators remain limited. We investigated the expression, functional role, and mechanism of CCM3 in ESCC and its relationship with the HIF-1α/VEGFA angiogenic axis.</p><p><strong>Methods: </strong>CCM3, HIF-1α, VEGFA and microvessel density (MVD, CD31) were assessed by immunohistochemistry in 53 paired ESCC and adjacent non-cancerous tissues. CCM3 knockdown was optimized using four siRNAs in KYSE-70 and KYSE270 cells. CCM3 siRNA 1064-A was selected as the most effective and optimal knockdown achieved at 8 nM, 48 h. Tumor-conditioned HUVECs (referred to as tumor-conditioned endothelial cells, TECs) were generated using conditioned media from knockdown cells; TEC proliferation (CCK8), migration (scratch), invasion (Transwell) and tube formation were evaluated in vitro. A subcutaneous xenograft model using KYSE-70 cells was employed in vivo, followed by intratumoral silencing of CCM3 to assess tumour development, proliferation (Ki-67), and microvessel density (CD31).</p><p><strong>Results: </strong>High endogenous CCM3 expression was significantly upregulated in ESCC tissues compared to adjacent non-cancerous tissues and correlated with clinicopathological features like depth of invasion, lymph node metastasis and advanced stage. CCM3 expression positively correlated with HIF-1α and VEGFA. CCM3 knockdown siRNA 1064-A attenuates TEC proliferation, migration, invasion and tube formation in vitro. In vivo, CCM3 knockdown reduced tumor growth, tumor weight, Ki-67, CD31 staining and levels of HIF-1α and VEGFA.</p><p><strong>Conclusions: </strong>High endogenous CCM3 expression associates with aggressive ESCC clinicopathological features and angiogenesis markers. CCM3 knockdown inhibits tumor-conditioned endothelial function, xenograft growth, intratumoral vascularization, and HIF-1α/VEGFA expression, warranting further mechanistic investigation.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2191-2212"},"PeriodicalIF":3.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-026-03132-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Angiogenesis is essential for esophageal squamous cell carcinoma (ESCC) progression, yet clinically actionable regulators remain limited. We investigated the expression, functional role, and mechanism of CCM3 in ESCC and its relationship with the HIF-1α/VEGFA angiogenic axis.

Methods: CCM3, HIF-1α, VEGFA and microvessel density (MVD, CD31) were assessed by immunohistochemistry in 53 paired ESCC and adjacent non-cancerous tissues. CCM3 knockdown was optimized using four siRNAs in KYSE-70 and KYSE270 cells. CCM3 siRNA 1064-A was selected as the most effective and optimal knockdown achieved at 8 nM, 48 h. Tumor-conditioned HUVECs (referred to as tumor-conditioned endothelial cells, TECs) were generated using conditioned media from knockdown cells; TEC proliferation (CCK8), migration (scratch), invasion (Transwell) and tube formation were evaluated in vitro. A subcutaneous xenograft model using KYSE-70 cells was employed in vivo, followed by intratumoral silencing of CCM3 to assess tumour development, proliferation (Ki-67), and microvessel density (CD31).

Results: High endogenous CCM3 expression was significantly upregulated in ESCC tissues compared to adjacent non-cancerous tissues and correlated with clinicopathological features like depth of invasion, lymph node metastasis and advanced stage. CCM3 expression positively correlated with HIF-1α and VEGFA. CCM3 knockdown siRNA 1064-A attenuates TEC proliferation, migration, invasion and tube formation in vitro. In vivo, CCM3 knockdown reduced tumor growth, tumor weight, Ki-67, CD31 staining and levels of HIF-1α and VEGFA.

Conclusions: High endogenous CCM3 expression associates with aggressive ESCC clinicopathological features and angiogenesis markers. CCM3 knockdown inhibits tumor-conditioned endothelial function, xenograft growth, intratumoral vascularization, and HIF-1α/VEGFA expression, warranting further mechanistic investigation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
食管鳞状细胞癌中CCM3表达与血管生成的关系及其可能机制
背景:血管生成是食管鳞状细胞癌(ESCC)进展的必要条件,但临床可操作的调节剂仍然有限。我们研究了CCM3在ESCC中的表达、功能作用、机制及其与HIF-1α/VEGFA血管生成轴的关系。方法:采用免疫组化方法检测53例配对ESCC及癌旁非癌组织的CCM3、HIF-1α、VEGFA及微血管密度(MVD、CD31)。在KYSE-70和KYSE270细胞中使用4种sirna对CCM3敲除进行优化。选择CCM3 siRNA 1064-A作为在8 nM, 48 h下实现的最有效和最佳的敲除。使用条件培养基从敲除的细胞中生成肿瘤条件HUVECs(称为肿瘤条件内皮细胞,TECs);评估TEC的增殖(CCK8)、迁移(scratch)、侵袭(Transwell)和试管形成。在体内采用KYSE-70细胞皮下异种移植模型,然后在瘤内沉默CCM3以评估肿瘤的发展,增殖(Ki-67)和微血管密度(CD31)。结果:与癌旁非癌组织相比,ESCC组织中高内源性CCM3表达显著上调,且与浸润深度、淋巴结转移及进展程度等临床病理特征相关。CCM3表达与HIF-1α、VEGFA呈正相关。CCM3敲低siRNA 1064-A可减弱TEC在体外的增殖、迁移、侵袭和成管。在体内,CCM3敲低可降低肿瘤生长、肿瘤重量、Ki-67、CD31染色以及HIF-1α和VEGFA水平。结论:高内源性CCM3表达与侵袭性ESCC临床病理特征和血管生成标志物相关。CCM3敲低抑制肿瘤条件内皮功能、异种移植物生长、瘤内血管形成和HIF-1α/VEGFA表达,需要进一步的机制研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍: The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
期刊最新文献
Correction: Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis. Correction: Efficacy and safety of endoscopic resection followed by chemoradiotherapy with S-1 plus cisplatin for esophageal cancer. Correction to: Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer. Current development and challenges of NK cell-based immunotherapy for gastrointestinal cancers. Circulating tumor DNA methylation and gut microbiota in colorectal cancer: diagnostic, prognostic, and therapeutic implications.
wanfang
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1